Merck & Co., Inc. Pushing The Throttle On Oncology

Merck is hoping that a tighter focus will lead to better growth.

Feb 6, 2014 at 6:30PM

Diversification has fallen somewhat out of favor in Big Pharma, as many companies are looking to a smaller number of larger therapeutic areas to generate better growth and cash flow. Merck (NYSE:MRK) is among them, as the company has made it clear that immuno-oncology is a top priority, along with hepatitis C (HCV) and vaccines to lesser extents.

It is certainly true that focusing intensely on oncology has done Roche (NASDAQOTH:RHHBY) no harm, and it is a path that Bristol-Myers Squibb (NYSE:BMY) is also choosing to follow. Merck also has some opportunities and options for restructuring its animal health and consumer businesses in a way that could add value. Although investor enthusiasm for immuno-onocology has driven these shares to a strong performance over the past year, they are not unreasonably priced for long-term investors.

It would seem that earnings barely matter
As I have commented in the past with companies like Bristol-Myers, the Street is giving only perfunctory attention to earnings releases these days unless there's a sizable miss. Merck's results were no exception.

Revenue was down 4% as reported, and down 1% in constant currency, and that was just a bit below the average Street guess. Pharmaceutical sales were down 3% (flat ex-foreign exchange), with Januvia/Janumet sales up 2% (making up more than 15% of pharma sales), Zetia up 6% and Remicade up 13%. Animal health sales were down 3% in reported terms, with consumer care down 1%.

Continuing the theme this quarter, Merck's margins were mixed. Gross margin was weaker than expected, falling two points, but the company made it up with lower SG&A and R&D spending. As a result, operating margins were slightly above expectations and Merck remains one of the stronger margin stories in the big pharma industry.

Time to shuffle the deck?
Concentration and focus is now in vogue in Big Pharma, and Merck looks to be following in the footsteps of Pfizer (NYSE:PFE) and others when it comes to restructuring its business. In particular, management has openly acknowledged that it is considering strategic options for its animal health and consumer/OTC businesses.

One of the more popular rumors is that Merck will trade with Novartis (NYSE:NVS) – swapping Merck's consumer business for the animal health and vaccine businesses of Novartis. While there would need to be some cash involved to make the deal balance, there's some appeal – Merck has a sub-scale consumer business and Novartis has a sub-scale vaccine business and both could likely benefit from the swap. The animal health part might be more problematic, as Merck's animal health business is large (second to Pfizer's former business Zoetis) and there may be antitrust issues that would interfere with this swap.

Even without Novartis's animal health business, it would be a deal worth considering. Vaccines are less than 5% revenue and contribute almost no profits to Novartis, while Merck's consumer health is tiny by Merck standards but would expand the Novartis consumer health business by roughly one-third and bring in brands like Claritin, Dr. Scholls, and Coppertone.

Full speed ahead in immuno-oncology
Merck has not been shy in professing its enthusiasm for immuno-oncology, with the CEO calling it a once-in-a-career opportunity and a top priority for R&D dollars. As I have written before, that enthusiasm is not at all misplaced, as this therapeutic class could ultimately be measured in the tens of billions of dollars of annual revenue opportunity. What's more, Merck's PD-1 compound MK-3475 (lambrolizumab) makes it a very serious contender against Bristol-Myers and Roche.

Comparing across early stage clinical trial results is problematic and often misleading, but the results seen to date from MK-3475 suggest that it is a legitimate candidate in melanoma and perhaps even better than Bristol-Myers' nivolumab in non-small-cell lung cancer (NSCLC). Merck has also managed to move much faster than expected, with a rolling submission for MK-3475 in melanoma already under way. Bristol-Myers' nivo will probably get to market first in NSCLC, but it now looks as though Merck will be first in melanoma. Although I believe the market is getting a little too hung up on time to market (and I believe Roche is may be slipping to "underrated" in immuno-oncology), it's still a strong step for Merck.

Merck is also moving aggressively to establish MK-3475 as a potential platform therapy. The company announced collaborations with Pfizer, Amgen, and Incyte to evaluate MK-3475 with other oncology therapies, including Pfizer's Inlyta and PF-2566. As Pfizer's oncology pipeline is arguably not up to scratch today (at least not in immuno-oncology), this could be a useful ride-along opportunity. It's also worth noting that the potential to combine immuno-oncology drugs with other oncology therapies is a major plus in Roche's column (due to its deep and broad oncology platform), so this is a logical competitive move for Merck.

The bottom line
Sell-side analysts have added more than $3 billion on average to their 2020 revenue estimates for Merck's pipeline, with a lot of that coming from immuno-oncology. That in turn has helped drive a 30% move in the shares over the past year, and it's hard to argue that Merck's shares have been overlooked. Only modest free cash flow growth (around 2%) is needed to support a fair value in line with today's price, though, and while I think it will be challenging for Merck to exceed that growth rate, I see the move in the shares as only taking Merck from under-valued to fairly valued, leaving the shares as a credible option for long-term investors.

Discover The Motley Fool's top stock for 2014-for free!
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Stephen D. Simpson, CFA owns shares of Roche. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information